Monitoring of a diabetic patient by Reusch, C E
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Monitoring of a diabetic patient
Reusch, C E
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-127473
Originally published at:
Reusch, C E (2016). Monitoring of a diabetic patient. In: ESVE, Summer School of Veterinary En-
docrinology, Bologna, Italy, 26 June 2016 - 1 July 2016.
Monitoring patients with diabetes mellitus 
Claudia E. Reusch 
The primary goals of therapy are to eliminate the clinical signs of diabetes while preventing 
short-term complications (hypoglycemia, DKA). Concurrent problems also need to be controlled, 
as they may render glycemic control difficult. The monitoring techniques are similar for dogs and 
cats. Different to dogs, however, cats may develop relevant stress hyperglycemia when brought 
to an unfamiliar environment and/or manipulated by a veterinarian. Stress hyperglycemia may 
render the interpretation of blood glucose concentrations and blood glucose curves, generated in 
the hospital, difficult. Measurement of blood glucose at home is less stressful or even stress-free 
when done by experienced owners and results of home-monitoring are usually more reliable 
than results generated in the hospital (Reusch 2015).  Another important difference between 
dogs and cats is the fact, that a substantial percentage of cats may experience diabetic 
remission, whereas remission is rare in dogs and usually only occurs after castration of a bitch 
with diestrus-associated diabetes. Diabetes remission is considered to be one of the major 
treatment goals in diabetic cats by some authors (Bloom and Rand 2014); the most recent 
guidelines on feline diabetes, however, do not list remission as a major treatment goal (Sparkes 
et al 2015).  
In dogs cataract formation is inevitable in most dogs, as many as 80% of dogs will develop 
cataracts within 16 months of diagnosis (Beam et al 1999). Cataract formation may be delayed 
with good glycemic control and avoidance of wide fluctuations of blood glucose (Nelson 2015).  
Management of a diabetic pet may be stressful for owners and may impair their own quality of 
life. Recent survey revealed areas with the most negative impact, such as “difficulties leaving 
dog/cat with family or friends”, “boarding difficulties” “vision (dog)”, “hypoglycemia”, “work life”, 
“social life”, “costs”,  “wanting more control” (Niessen et al 2010, 2012). It is, therefore, advisable 
to discuss with every single owner his/her biggest worries and curtail the treatment and 
monitoring plan accordingly. For instance, if hypoglycemia is the biggest worry one should avoid 
aggressive treatment protocols, if costs are a major concern it may be necessary to simplify the 
treatment, if more control is desired home-monitoring should be introduced (Sparkes et al 2015). 
Newly diagnosed diabetic animals should be monitored more frequently than established and 
stable diabetics. Initially, weekly re-checks are recommended, with improving glycemic control 
time intervals can be prolonged. The first 3 months is the most important time in the life of a 
diabetic pet due to several reasons: owner needs support to get familiar with the new 
challenges, diabetic remission may occur requiring reduction and cessation of insulin 
application, insulin resistance may become obvious requiring further work-up.  
 
History and physical examination 
The most important parameters to assess glycemic control are the clinical signs observed by the 
owner, the stability of the body weight and the findings during physical examination. Dogs and 
cats, in which the initial clinical signs (e.g. pu/pd, polyphagia, lethargy, poor hair coat) have 
resolved, the body weight stays within the desired range and physical examination reveals a 
good clinical condition, are usually well controlled. Weight gain above the desired range points to 
insulin overdose; in cats with poor glycemic control weight gain should raise the suspicion for 
hypersomatotropism.  Measurement of serum fructosamine concentration and generation of 
blood glucose curves will help to confirm the status of good or poor glycemic control, blood 
glucose curves are particularly useful for the “fine-tuning” of insulin therapy. Measurement of 
blood glucose will help to detect periods of hypoglycemia which may go otherwise unnoticed; 
increasing the insulin dose only on the basis of clinical signs may therefore be problematic. 
Blood glucose measurements will also help to determine if diabetic remission has occurred. 
Clinical signs are usually well controlled if most blood glucose concentrations are approximately 
between 4.5 and 15 mmol/l throughout 24 hours. In cats, however, clinical signs may not always 
match blood glucose concentrations, e.g. the cat may appear clinically much better than one 
would assume looking at the blood glucose levels (Norworthy and Wexler-Mitchell 2015).   
 
Serum fructosamine concentration 
Fructosamine is the product of an irreversible reaction between glucose and the amino groups of 
plasma proteins. Its concentration mainly depends on the blood glucose concentration (e.g. 
extent and duration of hyperglycemia) and the lifespan of plasma proteins; it is generally 
assumed that fructosamine reflects the mean blood glucose concentration of the preceding 1–2 
(-3) weeks. The reference ranges differ slightly between laboratories but are usually between 
approximately 200 and 360 mol/l. Fructosamine is higher in male than in female cats and lean 
cats have lower fructosamine than normal weight and obese cats  (Gilor et al 2010). In the vast 
majority of newly diagnosed diabetic dogs and cats, fructosamine levels are > 400 mol/l and 
may be as high as 1500 mol/l. Fructosamine is not affected by short-term changes in blood 
glucose concentration and thus is usually normal in cats with stress hyperglycemia (Reusch et al 
1993, Lutz et al 1995, Crenshaw et al 1996). However, in animals with a very recent onset of 
diabetes or with mild diabetes, serum fructosamine may be in the normal range, rendering  the 
differentiation between stress and diabetic hyperglycemia impossible.  In a recent study, two 
groups of healthy cats were infused with glucose to maintain either a marked or a moderate 
hyperglycemia (30 mmol/l or 17 mmol/l) for 42 days. In the group with marked hyperglycemia, it 
took 3 – 5 days until fructosamine exceeded the upper limit of the reference range, in the group 
with moderate hyperglycemia fructosamine concentrations mostly fluctuated just below the 
upper limit of the reference range (Link and Rand 2008). Of note, fructosamine is influenced by 
hypoproteinemia/hypoalbuminemia (decrease), hyperlipidemia (decrease, dogs), azotemia 
(decrease, dogs), hyperthyroidism (decrease), hypothyroidism (increase) and paraproteinemia 
(increase) (Reusch and Tomsa 1999, Graham et al 1999, Reusch and Haberer 2001, Reusch et 
al 2002, Zeugswetter et al 2010). In those circumstances, fructosamine should not be used to 
monitor glycemic control.  
After initiating insulin therapy, blood glucose concentrations usually start to decrease which is 
followed by a decrease in fructosamine after a few days. Generally, fructosamine concentrations 
increase when glycemic control worsens and decrease when glycemic control improves. We 
consider 50 µmol/l to be the so-called critical difference between consecutive measurements; a 
recent study found a lower critical difference of 33 µmol/l (Link and Rand 2008). Fructosamine is 
not affected by stress nor by lack of food intake, both are common in case of hospitalization. 
Routine measurement of fructosamine is therefore helpful to clarify the effects of stress or lack of 
food intake, generally spoken to clarify discrepancies between history and physical examination 
and blood glucose measurements.  Most well-controlled diabetic pets are slightly hyperglycemic 
for some time during a 24-hour period and consequently, fructosamine  will not become 
completely normal. In cats which achieve diabetic remission, however, fructosamine 
concentrations decrease into the normal range. As long as fructosamine is elevated (even if only 
slightly), the diabetes is not in remission. Fructosamine between approximately 350 and 450 
µmol/l reflects good glycemic control, concentrations between 450 and 550 µmol/l suggest 
moderate and concentrations above 550 – 600 µmol/l poor glycemic control. In the latter 
situation, fructosamine is not helpful to identify the underlying problem because the various 
possible reasons for poor regulation (e.g. application error, insulin underdose, too short duration 
of insulin effect, diseases causing insulin resistance, Somogyi phenomenon) are associated with 
high blood glucose concentrations. Fructosamine in the lower half of the reference interval (< 
300 µmol/l) suggests prolonged periods of hypoglycemia and/or diabetic remission or a 
concurrent problem causing a decrease in fructosamine. The ranges should be considered as a 
rough guideline, as there are substantial differences in glycation between individuals (Link and 
Rand 2008).  Fructosamine is useful if followed in individual patients over time, however, it 
should never be used as the sole indicator of the quality of metabolic control. The parameter is 
less important than the evaluation of clinical signs and body weight and generation of blood 
glucose curves. Shipping of sample for fructosamine measurement should be on cold packs if 
samples will be in transit for more than 24 hours. 
 
Urine glucose monitoring 
Glucose is freely filtered by the glomerulus and reabsorbed in the proximal tubules by the 
sodium-glucose cotransporter 2 (SGLT2). When the blood glucose concentration exceeds the 
so-called renal threshold (dogs approx. 12 – 12 mmol/l, cats approx. 15 – 17 mmol/l), glucose is 
excreted in the urine. The higher the blood glucose concentration is, the more glucose is found 
in the urine, which would in theory render the urine test a valuable monitoring tool.  However, 
measurement of urine glucose may be misleading for several reasons: 1) the result does not 
reflect the actual blood glucose concentration, but is an average over the time of urine 
accumulation in the bladder, 2) a negative urine test does not differentiate between 
hypoglycemia, normoglycemia or mild hyperglycemia, 3) hydration status and urine 
concentration may affect the result. 4) It is known from human diabetics that renal glucose 
excretion varies considerably between patients and also within the same patient. It has been 
suggested to re-evaluate the concept of renal glucose threshold (Pickup 2003, Rave et al 2006, 
Wolf et al 2009).  We strongly discourage owners to adjust the insulin dose on the basis of 
morning urine glucose measurements. Owners, who are unable to measure blood glucose but 
still want to do some type of monitoring, may be advised to use urine glucose measurements in 
all urine samples voided throughout one day per week. Persistent glycosuria would suggest 
inadequate glycemic control and the need for thorough evaluation in the hospital. If no glucose is 
detected in any of the samples, the pet is either very well controlled, in diabetic remission or is 
overdosed with insulin and should also be evaluated by a veterinarian. In dogs and cats prone to 
develop DKA, monitoring of urine ketone bodies may be helpful.  
 
Blood glucose measurements and blood glucose curves 
Generally, a single blood glucose concentration is helpful only if hypoglycemia is identified. 
Determination of blood glucose at the time of assumed glucose nadir is also unreliable, as time 
of nadir varies between animals and also within the same animal. Next to clinical signs serial 
measurements of blood glucose throughout the day (BGC) is the most important monitoring tool 
for diabetic dogs and cats. Ideally, BGCs are generated at home (HM) to avoid the influence of 
stress and lack of food intake on glucose measurements. Glucose should be measured before 
the insulin injection and every 2 hours thereafter until the next insulin injection is due, in case of 
suspected hypoglycemia measurement every hour may be required. If the glucose nadir is not 
reached during this time, insulin application should be delayed and glucose measurements 
should be continued. If a BGC is generated in the hospital the owner should give insulin and 
food at home and bring the animal to the hospital as soon as possible. Only glucometers 
validated for the dog and cat by an independent study should be used. Many glucometers 
designed for humans are plasma-calibrated and as the glucose content of erythrocytes differ 
markedly between pets and humans, those devices usually underestimate the glucose 
concentration in pets.  
Opinions on the question, how often owners should check their pet's blood glucose, differ. Some 
investigators have suggested that in cats measurements should be performed several times per 
day and adjust the insulin dose accordingly following a very tight dosing algorithm. Those 
algorithms are sometimes called “remission protocols” and it has been claimed that following 
those protocols leads to higher remission rates (Roomp and Rand 2009, Roomp and Rand 
2012). However, those intensive protocols require owners who have the time to measure several 
times per day and they bear a high risk of hypoglycemia, even when performed under close 
supervision. The recent ISFM guidelines do not recommend those protocols (Sparkes et al 
2015). Our protocol in Zurich foresees that owners generate a BGC once a week during the first 
months of therapy and generally 5-7 days after any adjustment in insulin dose. After stabilization 
(and if no remission is achieved in cats), the time intervals are prolonged to approximately every 
3 to 4 weeks. We also ask owners to measure the fasting blood glucose (pre-insulin glucose) 
twice weekly and to perform a spot glucose check whenever they feel uncertain about the well-
being of the cat. Although many of our owners work full-time, this protocol is feasible for most of 
them, as they generate the BGC during the weekend. There are cases in which we ask for 
additional BGCs (e.g. in an extremely unstable diabetic), but those are rare exceptions. Most 
owners appreciate the fact, that they have more control over the disease by performing HM, for 
a minority, however, HM may be an additional burden (Kley et al 2004).  
BGCs are extremely helpful for the titration of the insulin dose, either upwards or downwards. 
BGCs are assessed by evaluating the pre-insulin glucose, glucose nadir, duration of effect and 
degree of glucose fluctuations. The highest glucose concentration, which is usually (but not 
always) the fasting/pre-insulin concentration should not exceed 10 – 15 mmol/l, the nadir should 
ideally be between 4.5 – 7.8 mmol/l. Lower nadirs may be due to insulin overdose (including 
sudden improvement of insulin-resistant states), excessive overlap of insulin actions or lack of 
food intake. They may also be found in cats in which diabetes is ready to go into remission or is 
already in remission.  Finding a nadir below 70 mg/dl (3.9 mmol/l) should always lead to a 
reduction of the insulin dose. Dose changes are usually made in steps of 0.5 (-1.0) U in cats and 
in steps of 10-20% in dogs. The duration of effect is defined as the time from the insulin injection 
through the glucose nadir until the blood glucose concentration exceeds 10 – 15 mmol/l, it 
should be evaluated when the glucose nadir is within the target range and be ideally 
approximately 12 hours. If the duration is less than 8 – 10 hours, the patient usually reveals 
signs of diabetes, and if duration is longer than 14 hours the risk of hypoglycemia or the 
occurrence of the Somogyi effect increases. If those findings are persistent, a switch to a longer 
respectively shorter acting insulin should be made. Remission is defined as the situation in 
which the clinical signs of diabetes have resolved, serum fructosamine and blood glucose 
concentration are in the normal range and insulin therapy can be ceased. In cats in which all 
blood glucose measurements of a BGC range between 4.5 – 6.7 mmol/l and serum fructosamine 
concentration is < 350 µmol/l we start to reduce the insulin dose in steps of 0.5 U/cat BID every 
5 – 7 days. The owner is advised to monitor the cat closely with regard to re-appearance of 
clinical signs and a BGC is performed prior to each reduction step. The insulin is reduced until a 
dose of 0.5 U/cat BID is reached; if the blood glucose is still normal, insulin administration is 
terminated.  Close clinical monitoring and regular glucose measurement (e.g. fasting blood 
glucose twice per week) is recommended to ensure that there is no relapse of the disease. 
Reduction is done in larger steps than 0.5 U/cat if hypoglycemia is seen.  
It is important to realize, that BGCs can vary markedly from day to day, even when they are 
generated at home (Fleeman and Rand 2003, Alt et al 2007). It has been shown, that in cats 
with good glycemic control variability between BGCs is less than in cats with moderate or poor 
glycemic control (Alt et al 2007). One of the major advantages of home monitoring is that the 
veterinarian can ask the owner for more than one BGC before a treatment decision is made. 
This is of particular importance in pets that are difficult to regulate. Treatment decisions should 
never be made on the basis of BGCs alone, but should always include the interpretation of the 
clinical situation. 
 
Continuous glucose monitoring 
CGM systems measure interstitial fluid glucose concentrations and usually record the glucose 
concentration every 5 minutes. Systems such as the Guardian REAL-Time (Medronic) and the 
Dexcom G4 are useful for diabetic patients that are hospitalized for several days (e.g.in case of 
DKA). Transmission of data is wireless and only possible if the monitor is within 2-3 meters of 
the patient, therefore they are not suitable for HM. In contrast, the  CGMS iPro2 (Medtronic) 
records glucose values for up to 7 days without displaying the data on a monitor; instead, at the 
end of the monitoring period, the data are uploaded on a computer and evaluated 
retrospectively. Because the iPro2 does not involve a monitor, it can be used in the home 
environment and may be particularly useful in difficult to regulate diabetes pets (Salesov et al, 
submitted). 
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